Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Clinical

Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board

Abstract

Background

Germline testing is important in prostate cancer and evaluation can be complex.

Methods

We instituted a monthly multi-disciplinary virtual genetics tumor board (7/2021-3/2022). Participants and panelists were surveyed on usefulness and acceptability.

Results

101 participants attended a session, and 77 follow-up surveys were completed. Over 90% participants and 100% panelists endorsed usefulness of the case discussions and usability of the technology. The majority felt it provided new information they will use.

Conclusions

A multidisciplinary genetics board was successfully developed to address complexity in prostate cancer genetics. The virtual platform may enhance dissemination of expertise where there are regional gaps.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Loeb S, Giri VN. Clinical implications of germline testing in newly diagnosed prostate cancer. Eur Urol Oncol. 2021;4:1–9.

    Article  PubMed  Google Scholar 

  2. Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, et al. Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium. Clin Genitourin Cancer. 2019;17:275–82.e271.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72.

    Article  PubMed  Google Scholar 

  4. Hijazi MA, Prebay ZJ, Johnson A, Wilder S, Patel A, Mehra R, et al. Utilization of a virtual tumor board for the care of patients with renal masses: experience from a quality improvement collaborative. Urol Pract. 2023;10:380–8.

    Article  PubMed  Google Scholar 

  5. Valerio MR, Serretta V, Arico D, Fazio I, Altieri V, Baldari S, et al. A prospective observational study on the structuring process and implementation of a large regional, inter-hospital, virtual multidisciplinary tumor board on prostate cancer. Anticancer Res. 2023;43:501–8.

    Article  PubMed  Google Scholar 

  6. Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, et al. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation. Cancer Treat Res Commun. 2020;25:100212.

    Article  PubMed  Google Scholar 

  7. Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, et al. Helix: a digital tool to address provider needs for prostate cancer genetic testing in clinical practice. Clin Genitourin Cancer. 2022;20:e104–13.

    Article  PubMed  Google Scholar 

  8. Loeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri VN. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer Prostatic Dis. 2023;26:772–7.

    Article  PubMed  Google Scholar 

Download references

Funding

Funding

The ENGAGEMENT study was supported by the Department of Defense (080-27000-X17501).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization SL, HHC, CP, LG, VNG, Methodology SL, LG, SWK, AR, VNG, Formal Analysis AR, Investigation All authors, Data curation LG, Writing original draft SL, Writing review and editing All authors, Supervision VNG, Funding acquision SL, VNG.

Corresponding author

Correspondence to Stacy Loeb.

Ethics declarations

Competing interests

SL reports prior equity in Gilead, unrelated to this publication. HHC reports research funding to institution from Astellas, Clovis Oncology, Color Foundation, Janssen, Medivation, Promontory Therapeutics, Sanofi; Consultant to AstraZeneca; Royalties from UpToDate. CJP reports consulting for Bayer. FH reports educational consultant for AstraZeneca. The remaining authors report no relevant COI.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Loeb, S., Cheng, H.H., Paller, C.J. et al. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-023-00778-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41391-023-00778-9

Search

Quick links